Ghrelin Antagonist Cuts Fentanyl Use in Rats
A ghrelin antagonist called PF5190457 reduced fentanyl self-administration in male rats without major side effects, new preclinical research shows.
Section
Regulation
FDA decisions, legal rulings, and policy — decoded.
Looking for background? Browse the peptide research library — cited overviews of every compound, sorted by evidence tier.
-
-
CGRP Peptides: Migraine Safety in Focus
New real-world and review data on CGRP peptides—eptinezumab and gepants—reveal safety and effectiveness signals in migraine patients. What the studies found.
-
Peptide Access: State Laws Under Scrutiny
New research examines peptide access across U.S. states, revealing how regulatory gaps shape availability in sexual medicine and beyond.
-
GLP-1 Peptides: Joint Surgery Outcomes
New meta-analysis links GLP-1 receptor agonists to better 90-day outcomes after hip and knee replacement. What the preclinical and clinical data show.
-
IL-5 Biologics: FDA Approvals Explained
IL-5 biologics have reshaped eosinophil disease treatment. Learn what clinical and preclinical studies reveal about IL-5-targeted FDA-approved therapies.
-
Biologic Safety: 3 Peptide Studies Reviewed
New research examines biologic safety across psoriasis, hypoparathyroidism, and COPD—here's what the clinical and meta-analysis data show.
-
Peptide Access: State Rules vs. FDA
New research maps how state-level rules shape peptide access in sexual medicine, often bypassing FDA oversight. Here's what the data found.
-
PTH Analogs: Safety Signals Reviewed
A new meta-analysis examines PTH analogs for hypoparathyroidism, revealing clinical efficacy and safety signals across multiple randomized trials.
-
Icotrokinra FDA Approval: What It Means
Icotrokinra just cleared FDA review. Here's what the approval data reveal about this IL-13 receptor peptide and its regulatory significance.
-
Peptide Biohacking: Gray-Market Safety Risks
Peptide biohacking is surging online, but gray-market access raises serious public health risks. Here's what the latest research reveals.
-
BPC-157 Regulation: What the Science Says
New research maps the BPC-157 regulatory landscape: formulation hurdles, state-level access gaps, and what translational barriers mean for patients.
-
The End of the Compounding Era for GLP-1 Drugs
The GLP-1 shortage is over, and the FDA is closing compounding for semaglutide and tirzepatide. Deadlines, lawsuits, safety data, and what patients should know.
-
The Peptide Reckoning: The FDA's July 2026 Hearing on BPC-157
The FDA's advisory committee weighs BPC-157, TB-500, and five other peptides on July 23–24, 2026. What's at stake, and what the evidence really shows.
-
Washington Takes Aim at the Weight-Loss Ad
The FDA and HHS targeted deceptive drug ads in 2025, including GLP-1 telehealth marketing. What the crackdown covered and what patients should watch.
-
A Weight-Loss Drug, Approved for a Liver Disease
In August 2025 the FDA approved semaglutide (Wegovy) for MASH — the first GLP-1 cleared for a liver disease. What the accelerated approval requires.
-
Two Oral GLP-1s, Two Very Different Molecules
The FDA cleared oral semaglutide (a peptide) and orforglipron (a small molecule) months apart. How the two GLP-1 pills differ — and why chemistry matters.
-
FDA Proposes 'No Clinical Need' to Compound GLP-1 Drugs From Bulk Ingredients
The agency's proposed determination would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredient, unless a new shortage intervenes.
Frequently Asked Questions
What is the FDA advisory committee hearing scheduled for July 23–24, 2026, and why does it matter?
An FDA advisory committee is scheduled to meet on July 23 and 24, 2026, to review seven peptides — including BPC-157, TB-500, and Semax — for placement on a list that determines which substances licensed pharmacists may legally compound. The outcome of this review is significant because it directly affects whether compounding pharmacies can legally prepare and dispense these peptides to patients. This is a regulatory process, not a clinical endorsement or rejection of any peptide's effectiveness. Readers interested in how this affects their access to compounded medications should consult a licensed healthcare professional. This content is not medical advice.
What does it mean for a substance to be on or off the FDA's compounding list?
The FDA maintains lists that govern which bulk active ingredients compounding pharmacies are permitted to use when preparing medications. If a substance is placed on the list of substances that may be compounded, pharmacists may legally include it in compounded preparations under applicable regulations. If a substance is excluded or not included, compounding pharmacies generally cannot legally use it. The July 2026 advisory committee hearing for BPC-157 and other peptides is part of this review process. Individuals with questions about access to specific compounded medications should speak with a licensed pharmacist or physician. This content is not medical advice.
What is the FDA's proposed determination regarding GLP-1 drugs like semaglutide and tirzepatide?
As of May 1, 2026, the FDA proposed a 'no clinical need' determination that would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredients. This proposed rule would apply unless a new drug shortage occurs that might change the regulatory situation. This is a proposed determination, meaning it was not yet finalized as of that reporting date. Patients currently using or considering compounded GLP-1 medications should discuss implications with a qualified healthcare provider. This content is not medical advice.
What is the difference between an outsourcing facility and a traditional compounding pharmacy in this regulatory context?
Based on the reporting from Peptide News Network, the FDA's proposed GLP-1 determination specifically targets outsourcing facilities compounding from bulk active ingredients, which is a distinct regulatory category from traditional compounding pharmacies. Outsourcing facilities operate under Section 503B of the Federal Food, Drug, and Cosmetic Act and can compound medications without individual patient prescriptions for distribution to healthcare facilities, while traditional pharmacies operate under different rules. The regulatory distinctions between these categories affect which rules and proposed determinations apply to each. For specific legal or clinical questions, consult a licensed clinician or regulatory attorney. This content is not medical advice.
What peptides are under review at the July 2026 FDA advisory committee hearing?
According to Peptide News Network's reporting, the July 23–24, 2026 FDA advisory committee is reviewing seven peptides, with BPC-157, TB-500, and Semax specifically named in coverage. The review is focused on determining their status for the list governing legal compounding. The reporting does not specify all seven peptides by name. This regulatory review is a policy and legal process; it does not itself constitute medical guidance about these substances. Anyone with health questions related to these peptides should consult a licensed healthcare professional. This content is not medical advice.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for any medical concerns, diagnosis, or treatment.